A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

Outcome of poor prognostic phenotype non-Hodgkin lymphoma treatment among HIV-positive patients compared with HIV-negative counterparts in the HAART era: Experience from Hurlingham Oncology Clinic, ...

R-CHOP is a combination of five drugs that work together to target and kill cancer cells. It’s a first-line treatment for aggressive non-Hodgkin’s lymphoma, a group of blood cancers. Most often, ...

TTP following R-CHOP is a strong prognostic factor for survival in R/R DLBCL, with shorter TTP linked to poorer outcomes. Real-world data shows patients with TTPs under 12 months have lower survival ...

For patients with B-cell lymphoma, the addition of Revlimid to standard R-CHOP did not improve progression-free survival nor event-free survival. The addition of Revlimid (lenalidomide) to standard ...

Results presented at the 63rd Annual American Society of Hematology Meeting showed that using polatuzumab vedotin instead of vincristine in R-CHOP improved progression-free survival in patients with ...

Please provide your email address to receive an email when new articles are posted on . The regimen conferred a 71% complete response rate among older adults with newly diagnosed DLBCL. Median PFS and ...

The replacement of vincristine with Velcade (bortezomib) in the R-CHOP regimen for the treatment of transplantation-ineligible patients with newly diagnosed mantle cell lymphoma improved overall ...

To participate in this study, patients were required to have a diagnosis of de novo DLBCL; be treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone (R-CHOP) with or without ...